Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
Rhea-AI Summary
Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.
Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EBS declined 5.07%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $20M from the company's valuation, bringing the market cap to $376M at that time.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025.
Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) report Q2 2025 earnings?
How can investors join the Emergent BioSolutions Q2 2025 earnings call?
Will there be a replay available for Emergent BioSolutions Q2 2025 earnings call?
Do I need to register in advance for Emergent BioSolutions' Q2 earnings call?
